Amyloid Beta Expression Constructs for Toxicity Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective tools for screening compounds or genetic factors that modulate amyloid beta-induced toxicity, which is a key aspect of neurodegenerative diseases like Alzheimer's, as existing technologies do not adequately address the toxicity associated with amyloid beta peptides in cellular models.
Innovation Solution
Development of expression constructs in yeast and mammalian cells that encode a polypeptide with a signal sequence and a Golgi-directing pro sequence, along with a human amyloid beta protein, allowing for the induction of toxicity and subsequent screening for compounds or genetic factors that prevent or suppress this toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If expression constructs encoding human amyloid beta protein are introduced into yeast or mammalian cells, then the ability to screen for compounds that modulate amyloid beta-induced toxicity is enabled, but significant toxicity is induced in the host cells
Solution Approach 1:
The patent uses yeast and mammalian cells as intermediary models that can be engineered to express human amyloid beta protein. These intermediary systems allow screening for compounds that protect against toxicity without requiring direct testing in human neural tissue, thus enabling the screening capability while containing the toxicity within the model system.
Solution Approach 2:
The patent converts the harmful toxicity of amyloid beta expression into a beneficial screening tool. By intentionally expressing amyloid beta in controlled cell models, the system creates a toxic environment that can be used to identify protective compounds, thus transforming the harmful effect into a useful assay for drug discovery.
2Productivity
If amyloid beta protein is expressed in cellular models, then compounds that prevent or suppress toxicity can be identified, but the complexity of managing toxic effects and screening assays increases
Solution Approach 1:
The patent segments the complex problem of Alzheimer's disease research into manageable parts by creating separate, standardized cell-based assay systems. Each assay is designed to test specific aspects of amyloid beta toxicity, allowing high-throughput screening of compounds without requiring complex integrated systems.
Solution Approach 2:
The patent employs parameter changes by using different cell types (yeast and mammalian cells), different expression constructs, and varying expression levels to optimize the balance between producing sufficient amyloid beta for screening and maintaining cell viability. This allows tuning of the assay sensitivity and complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the identification of compounds and genetic factors that can mitigate amyloid beta-induced toxicity, providing potential therapeutic options for neurodegenerative diseases by using yeast and mammalian cell models to assess the impact of amyloid beta expression constructs.
Implementation Method 1
A signal sequence causes the polypeptide containing it to be targeted to the endoplasmic reticulum within a cell
Implementation Method 2
A Golgi-directing pro sequence causes the transport of the polypeptide containing it to the Golgi
Data Source
Figure 1A~1B
Figure 2
Figure 3
AI summary
Disclosed are yeast expression constructs encoding a polypeptide containing a signal sequence, a Gol gi -di recti ng pro sequence, and a human amyloid beta protein, and mammalian expression constructs encoding a polypeptide containing a selected signal sequence and a human amyloid beta protein. Also disclosed are methods of screening cells to identify compounds that prevent or suppress amyloid beta-induced toxicity and genetic suppressors or enhancers of amyloid beta-induced toxicity. Compounds identified by such screens can be used to treat or prevent neurodegenerative disorders such as Alzheimer's disease.